Changes are coming in 2026 for GLP-1 drugs. Long defined by high prices, shortages and weekly injections, drugs including ...

There's a new pill and new ways to pay for the weight-loss drugs known as GLP-1s.

At least 12% of adults in the U.S. have been prescribed a glucagon‐like peptide‐1 drug for one or multiple indications, but ...

Over half a million Californians could lose access to the hugely popular GLP-1 weight loss drugs starting Jan. 1, 2026, after ...

The Wegovy pill is expected to hit the market in January, joining injectable GLP-1 drugs that have transformed obesity treatment. One form you swallow, the other you inject. What else is different?

There’s “quite big news” around weight loss medications circulating right now, says Wajahat Mehal, MD, director of Yale ...

Low-income Californians who use Wegovy and similar weight loss drugs will lose their coverage in January. California and ...

Novo Nordisk plans to sell its newly approved obesity pill directly to patients at a lower price than a competing medicine ...

Novo Nordisk received approval from the U.S. FDA for the Wegovy pill (once-daily oral semaglutide 25 mg) to reduce excess ...

Drug pricing in the U.S. has always been complex, and having more prices be public may make it hard for patients to understand Prices are going down for Novo Nordisk's weight-loss drug Wegovy. How ...

Please provide your email address to receive an email when new articles are posted on . Semaglutide 2.4 mg was tied to reduced risk for major adverse cardiovascular events in certain patients with ...

Vanda Pharmaceuticals’ expansion into the booming GLP-1 market has cleared a midphase test. With the trial linking tradipitant to reduced nausea and vomiting in Wegovy patients, the biotech is gearing ...